<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               ADVERSE REACTIONS<BR>               <BR>                  Adverse events occurring at a rate of ≥3%, excluding those reported more commonly in placebo, encountered in the INNOPRAN XL placebo-controlled hypertension trials and plausibly related to treatment are shown in Table 1.<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Refid_5ae5d631-3474-4af0-a27e-7772b1b13"><BR>                     <caption>Table 1. Treatment Emergent Adverse Events Reported In &#8805;3% of Subjects</caption><BR>                     <col width="26%"/><BR>                     <col width="10%"/><BR>                     <col width="10%"/><BR>                     <col width="10%"/><BR>                     <tbody><BR>                        <tr><BR>                           <td styleCode="Rrule Botrule Lrule Toprule "/><BR>                           <td styleCode="Rrule Botrule Toprule "/><BR>                           <td align="center" colspan="2" styleCode="Rrule Botrule Toprule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">INNOPRAN XL</content><BR>                              </paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "/><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">Placebo</content><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">80 mg</content><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">120 mg</content><BR>                              </paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">Body System</content><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">(N=88)</content><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">(N=89)</content><BR>                              </paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph><BR>                                 <content styleCode="bold">(N=85)</content><BR>                              </paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph>Fatigue</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>3 (3.0%)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>4 (5.0%)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>6 (7.0%)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Lrule Botrule "><BR>                              <paragraph>Dizziness (except vertigo)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>2 (2.0%)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>6 (7.0%)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>3 (4.0%)</paragraph><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Rrule Botrule Lrule "><BR>                              <paragraph>Constipation</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>0</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>3 (3.0%)</paragraph><BR>                           </td><BR>                           <td align="center" styleCode="Rrule Botrule "><BR>                              <paragraph>1 (1.0%)</paragraph><BR>                           </td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR>The following adverse events were observed and have been reported with use of formulations of sustained- or immediate-release propranolol.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Cardiovascular<BR>                     <BR>                        Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Central Nervous System<BR>                     <BR>                        Light-headedness, mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate-release formulations, fatigue, lethargy, and vivid dreams appear dose related.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Gastrointestinal<BR>                     <BR>                        Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Allergic<BR>                     <BR>                        Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions; pharyngitis and agranulocytosis; erythematous rash, fever combined with aching and sore throat, laryngospasm, and respiratory distress.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Respiratory<BR>                     <BR>                        Bronchospasm.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Hematologic<BR>                     <BR>                        Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Skin<BR>                     <BR>                        Stevens-Johnson syndrome; toxic epidermal necrolysis; exfoliative dermatitis; erythema multiforme; urticaria.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Musculoskeletal<BR>                     <BR>                        Myopathy, myotonia (see PRECAUTIONS).<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Autoimmune<BR>                     <BR>                        In extremely rare instances, systemic lupus erythematosus has been reported.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Miscellaneous<BR>                     <BR>                        Alopecia, LE-like reactions, psoriasiform rashes, dry eyes, male impotence, and Peyronie’s disease have been reported rarely. Oculomucocutaneous reactions involving the skin, serous membranes, and conjunctivae reported for a beta blocker (practolol) have not been associated with propranolol.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>